VS
VSTM.O
—
NASDAQ
Biotechnology
Vstm.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
440,0M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-550,3 %
ROE
-366,2 %
Net margin
-677,6 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$6,10
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Verastem Inc operates in the biotechnology sector, developing therapies for cancer and autoimmune diseases, though the provided classification data contains conflicting sector assignments.
Business. Verastem Inc operates in the biotechnology sector, developing therapies for cancer and autoimmune diseases, though the provided classification data contains conflicting sector assignments.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY9 analysts
9 buy0 hold0 sell
Avg 12m price target16,38
Analyst recommendations
9 analysts · consensus BuyBuy9
Hold0
Sell0
12-month price target
16,38
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
9 analysts · indicative
Ownership→
Franklin Advisers, Inc.
largest disclosed fund holder
Profitability→
-366,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to VSTM.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Peers
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated · BP (BP)
- EarningsQ3 2026 earnings (expected)2026-10-30 · estimated · Chevron (CVX)
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Verastem Inc operates in the biotechnology sector, developing therapies for cancer and autoimmune diseases, though the provided classification data contains conflicting sector assignments.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDVerastem Inc maintains a strong liquidity position with cash and equivalents of $204.99 million against total liabilities of $189.25 million, resulting in a debt-to-equity ratio of 0.0. The company reports a market capitalization of $451.67 million and a price-to-book ratio of 7.9, indicating a premium valuation relative to its book value of $57.20 million. Operating cash flow is negative at -$137.51 million, reflecting the capital-intensive nature of its current operations.
The company is currently unprofitable, reporting a net income loss of $209.47 million and an operating income loss of $170.13 million on revenue of $30.91 million. Return on equity stands at -3.66, and return on assets is -0.85, highlighting significant erosion of shareholder value in the current period. The negative EV/EBITDA of -1.45 and high EV/Revenue of 7.98 suggest that the market is pricing in future growth potential rather than current earnings power.
Revenue concentration data is not provided in the available segments or geography sections, preventing a detailed analysis of product or regional mix. The total revenue of $30.91 million serves as the baseline for current operational scale.
Historical period data for revenue and net income trends is absent, limiting the ability to assess the trajectory of growth or profitability over time. The current financial snapshot represents the latest normalized period without comparative historical context.
Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The absence of debt and the presence of substantial cash reserves mitigate near-term solvency concerns.
Recent news observations indicate system reconciler events related to analysis job queuing for Verastem Inc, rather than specific corporate actions or market-moving news. Analyst sentiment appears positive, with a mean recommendation of 1.67 (strong buy) and a mean price target of $16.38, significantly above the current market price of $5.81.
Key takeaways
- Verastem holds a strong balance sheet with $204.99 million in cash and zero debt, providing a buffer against operational losses.
- The company is currently unprofitable with a net loss of $209.47 million, driven by high operating expenses relative to $30.91 million in revenue.
- Analysts maintain a strong buy consensus with a mean price target of $16.38, implying significant upside from the current $5.81 share price.
- Classification data is conflicting, with sector classification codes identifying the company as Biotechnology while rule-based systems assign it to Oil & Gas.
- Dilution risk is assessed as low, with basic and diluted shares outstanding identical at 77.74 million.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$5,66
Market cap
$451.7M
Enterprise valueⓘ
$246.7M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
7.9x
P / Tangible bookⓘ
7.9x
Tangible book
$57.2M
Net cashⓘ
$205.0M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-85.0%
ROEⓘ
-3.7%
Cash conversionⓘ
66.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Partners1
AMGEN INC.AMGN.OPartner95%Source ↗
Supply chain
Vendors → VSTM ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,65
Predicted surprise
+0,00
Beat probability
45 %
Analysts
9
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-08-01 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,58 |
| Revenue | —no estimate | —no estimate | 102,3M USD |
| Operating income | —no estimate | —no estimate | -171,7M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 5 %
Probability
5 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-23 · 1,8× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution9 analysts
Strong buy3
Buy6
Hold0
Sell0
Strong sell0
12-month price target$15,12 · Median $15,50
Low $8,00High $18,00
Operating income · consensus-171,7M USD
EPS surprise
−91,1 %
reported vs consensus · miss
Revenue surprise
−69,8 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$14,00
Mean$16,38
Median$16,00
High$19,00
Spot$5,66
+189.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-550,3 %Below median
Net Margin-677,6 %Below median
ROE-366,2 %Bottom quartile
D/E0,00Above median
Cash Conv0,66Below median
Corporate actions / M&A
M&A probabilityconf —
Probability
5 %
Base rate
3 %
Band
Moderate
180-day horizon · target 2027-01-23 · 1,8× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 200 000 sh1 grants1 insiders
- Director, President of Development · Stock Option (right to buy) → Common StockAcquired 200 000 @ $6,88grant · 2026-01-06
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Verastem, Inc. Market data — financials · 2026-08-01
- reconciler_enqueue (reconciler) on VSTM.O · 2026-08-01
- Verastem Inc Market data — analyst estimates · 2026-08-01
- VSTM.O HA canonical relationships · 2026-08-01
- Vistra Corp — company reference export (2026-07-05) · 2026-08-01
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$32M
- Investment Managers · as of 2026-03-310,00 %$3M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2024-06-300,00 %$5M
- Funds · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2022-09-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Daniel W PatersonPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 16 sellsnet -$341K11 insiders · last 365d
- Director, President and CEO · Common StockSold 20 871 @ $4,18$87K · 2026-06-22
- Chief Financial Officer · Common StockSold 57 @ $4,13$235 · 2026-06-22
- Chief Financial Officer · Common StockSold 4 032 @ $4,18$17K · 2026-06-22
- Director · Common StockOther 36 000 · 2026-05-21
- Director · Common StockOther 36 000 · 2026-05-21
- Director · Common StockOther 36 000 · 2026-05-21
- Director · Common StockOther 36 000 · 2026-05-21
- Director · Common StockOther 36 000 · 2026-05-21
- Director · Common StockOther 108 000 · 2026-05-21
- Director · Common StockOther 36 000 · 2026-05-21
- Director · Common StockOther 36 000 · 2026-05-21
- Director, President and CEO · Common StockSold 806 @ $5,82$5K · 2026-05-04
- Chief Financial Officer · Common StockOther 57 @ $5,74$327 · 2026-03-20
- Director, President and CEO · Common StockSold 970 @ $6,69$6K · 2026-02-04
- Chief Financial Officer · Common StockOther 16 665 · 2026-01-21
- Director, President and CEO · Common StockOther 213 785 · 2026-01-21
- Chief Financial Officer · Common StockSold 5 039 @ $7,16$36K · 2026-01-12
- Director, President and CEO · Common StockSold 10 321 @ $7,16$74K · 2026-01-12
- Chief Financial Officer · Common StockSold 80 @ $7,86$629 · 2025-12-24
- Director · Common StockSold 283 @ $9,14$3K · 2025-12-16
- Director, President and CEO · Common StockSold 393 @ $9,14$4K · 2025-12-16
- Director · Common StockSold 592 @ $9,14$5K · 2025-12-16
- Director, President and CEO · Common StockSold 2 000 @ $10,00$20K · 2025-12-11
- Director, President and CEO · Common StockSold 2 000 @ $10,07$20K · 2025-12-10
- Director, President and CEO · Common StockSold 2 000 @ $10,25$20K · 2025-12-09
Short positioning
20.1Mshares short-16.7% vs prior
6.83days to cover
63.7%short of daily vol
183.1Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
VSTM.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companyPeerSectorPartners
Evidence & claims
From filings & derived data- Revenue (annual): USD 30.91MUnknown
- Current assets (annual): USD 223.41MUnknown
- Total liabilities (annual): USD 189.25MUnknown
- Operating income (annual): USD -170.13MUnknown
- R&D expense (annual): USD 114.6MUnknown
- Operating cash flow (annual): USD -137.51MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -3Unknown
- Pre-tax income (annual): USD -209.47MUnknown
- Shares outstanding (annual): 77.74MUnknown
- EPS (basic) (annual): USD-PER-SHARES -3Unknown
- Cash & equivalents (annual): USD 204.99MUnknown
- Net income (annual): USD -209.47MUnknown
- Interest expense (annual): USD 1.14MUnknown
- Current liabilities (annual): USD 72.27MUnknown
- Total assets (annual): USD 246.44MUnknown
- Shareholders' equity (annual): USD 57.2MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -4Unknown
- Pre-tax income (annual): USD -130.45MUnknown
- Operating cash flow (annual): USD -104.77MUnknown
- Net income (annual): USD -130.64MUnknown
- Long-term debt (annual): USD 40.72MUnknown
- Capex (annual): USD 28KUnknown
- Current assets (annual): USD 94.96MUnknown
- EPS (basic) (annual): USD-PER-SHARES -4Unknown
Showing 24 of 34 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-28 03:14 UTCHOLDERInstitutional holding changed
2026-06-28 03:14 UTCHOLDER1 institutional position change flagged
2026-06-22 00:00 UTCINSIDER3 insider transactions — 2026-06 · net sell $104k
2026-06-22 00:00 UTCINSIDER3 insider transactions — 2026-06 · net sell $104k
2026-06-22INSIDERPaterson Dan sold 20.9k sh — Director, President and CEO ~$87k
2026-06-22INSIDERCalkins Daniel sold 57 sh — Chief Financial Officer ~$0k
2026-06-22INSIDERCalkins Daniel sold 4.0k sh — Chief Financial Officer ~$17k
2026-05-21 00:00 UTCINSIDER9 insider transactions — 2026-05
2026-05-21 00:00 UTCINSIDER9 insider transactions — 2026-05
2026-05-21INSIDERStuglik Brian M transacted 36.0k sh — Director
2026-05-21INSIDERJOHNSON JOHN transacted 36.0k sh — Director
2026-05-21INSIDERBunn Paul A. transacted 36.0k sh — Director
2026-05-21INSIDERKapur Anil transacted 36.0k sh — Director
2026-05-21INSIDERROBERTSON MICHELLE transacted 36.0k sh — Director
2026-05-21INSIDERBAILEY MICHAEL P transacted 108.0k sh — Director
2026-05-21INSIDERTollefson Karin Anna transacted 36.0k sh — Director
2026-05-21INSIDERRowinsky Eric K transacted 36.0k sh — Director
2026-05-04INSIDERPaterson Dan sold 806 sh — Director, President and CEO ~$5k
2026-03-20 00:00 UTCINSIDER1 insider transaction — 2026-03
2026-03-20 00:00 UTCINSIDER1 insider transaction — 2026-03
2026-03-20INSIDERCalkins Daniel transacted 57 sh — Chief Financial Officer ~$0k
2026-02-04 00:00 UTCINSIDER1 insider transaction — 2026-02
2026-02-04 00:00 UTCINSIDER1 insider transaction — 2026-02
2026-02-04INSIDERPaterson Dan sold 970 sh — Director, President and CEO ~$6k
2026-01-21INSIDERCalkins Daniel transacted 16.7k sh — Chief Financial Officer
2026-01-21INSIDERPaterson Dan transacted 213.8k sh — Director, President and CEO
2026-01-12INSIDERCalkins Daniel sold 5.0k sh — Chief Financial Officer ~$36k
2026-01-12INSIDERPaterson Dan sold 10.3k sh — Director, President and CEO ~$74k
2026-01-06INSIDERKauffman Michael acquired 200.0k sh Stock Option (right to buy) — Director, President of Development
Showing the 40 most recent of 50 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage